Nice, France - May 1 2019 - Iris Pharma’s highly skilled and experienced staff has validated a new model of chronic uveitis, with the anatomic site of inflammation affecting both anterior and posterior segments of the eye. This experimental model of panuveitis was induced by the Mycobacterium tuberculosis H37Ra antigen in preimmunized rabbits.
Uveitis is an intraocular inflammation that partly or totally affects the iris, ciliary body and choroid, the causes of which are not always known and may be varied: ocular trauma or systemic diseases of genetic, immune or infectious origin. Uveitis can be acute or chronic. During chronic uveitis, the untreated and prolongated inflammation can spread and affect other ocular structures, such as the lens, vitreous gel, retina or optic nerve, leading to cataracts, glaucoma or macular edema, which leads to loss of vision.
